Latest News for 05/2022
30 Nov 2020
The o2h human health EIS Fund has announced its intention to lead an investment into In4Derm, an innovative drug discovery company that is developing next generation topical and oral therapies for widespread inflammatory conditions such as eczema and rheumatoid arthritis. Syndicating with o2h ventures are Meltwind and Wren to complete a first investment in In4Derm. A spin out from the School, the team has been recognised as Scotland’s top spin out opportunity for 2020 having won the top prize in the 2019 Converge Challenge competition.
01 Sep 2020
University of Dundee researchers hope to turn their spinout venture into a biotech company worth hundreds of millions of pounds by helping to treat people with eczema, rheumatoid arthritis and other inflammatory conditions.
26 Sep 2019
Dr Andrew Woodland has been named the winner of the 2019 Converge Challenge, scooping £78,000 to develop his new drug discovery company, In4Derm. At a glittering reception at V&A Dundee, Dr Woodland triumphed over 17 fellow academic entrepreneurs with his business, which re-engineers oral drugs and turns them into novel topical drugs to improve the lives of patients living with skin diseases such as eczema.
19 Sep 2019
Two academic entrepreneurs from the division of Biological Chemistry and Drug Discovery have made the final of the Converge Challenge 2019. Andrew Woodland (In4Derm) and Michael Conneely (Ten Bio) will now go head-to-head against six other entrepreneurs leading both start-ups and spin-outs at the Converge Awards Final which takes place at the iconic V&A, Dundee later this month.
29 May 2019
Around 60 aspiring entrepreneurs from across Scotland’s Universities are now through to the next stage of Converge, Scotland’s leading academic enterprise programme. Five projects from the University of Dundee, two from the School, have been selected for this stage of the Challenge. The projects from researchers based in Life Sciences are Ten Biotech and In4Derm.
04 Aug 2017
A collaboration between Professor Julian Blow’s lab in Gene Regulation and Expression and the Drug Discovery Unit has provided insights into how differences between normal cells and cancer cells could provide a novel anti-cancer therapy. The work, which involved the identification of a new class of small molecules that inhibit DNA replication, has been published in Cell Chemical Biology.